Cytokinetics Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Cytokinetics Inc
63.15
−5.67%
vs ±7.7% implied · ×0.73
shaded = implied · ▲▼ = realized
Cytokinetics has 2 disclosed suppliers and 4 disclosed customers in SEC filings.
SentencePursuant to the RP Ulacamten RPA, RPI ICAV purchased the right to receive 1 % of annual net sales of ulacamten by us, our affiliates or licensees, in exchange for $ 50 million which was paid up-front.
CYTK 10-Kaccession 0001193125-26-076495
SentenceIn February 2017, we entered into the RP OM RPA pursuant to which we sold a portion of our right to receive royalties from Amgen on future net sales of omecamtiv mecarbil to RPFT for a one-time payment of $90 million, which is non-refundable even if omecamtiv mecarbil is never commercialized.
SentenceIn December 2024, Corxel assigned its rights and obligations under our license and collaboration agreement to Genzyme Corporation, an affiliate of Sanofi.
SentenceIn November 2024, we entered into a license and collaboration agreement with Bayer Consumer Care AG, an affiliate of Bayer AG, pursuant to which we granted to Bayer an exclusive license to develop and commercialize aficamten in Japan, subject to certain reserved development rights.
CYTK 10-Kaccession 0001193125-26-076495
SentenceIn December 2024, we entered into a mutual termination agreement with Corxel to terminate the Corxel OM License Agreement.
CYTK 10-Kaccession 0001193125-26-076495
Linked news
Expected move
Inputs8Q avg ±4.1%·×1.86·rich
straddle ±9.7%
spot 62.99exp Nov 20ATM strike 62.5ATM straddle 7.23IV 60%